NCT00279825 - Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG

IPX054 200 mg

IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa

DRUG

IPX054 250 mg

IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa

DRUG

CD-LD IR

Active comparator containing 25 mg carbidopa and 100 mg levodopa

DRUG

CD-LD CR

Active comparator containing 50 mg carbidopa and 200 mg levodopa

DRUG

IPX054 200 mg Placebo

Placebo to match IPX054 200 mg

DRUG

IPX054 250 mg Placebo

Placebo to match IPX054 250 mg

DRUG

CD-LD IR Placebo

Placebo to match CD-LD IR

DRUG

CD-LD CR Placebo

Placebo to match CD-LD CR

Trial Locations (2)

Quest Research Institute, Bingham Farms

Oregon Health Sciences University - Parkinson's Center of Oregon, Portland